Skip to main content
Toggle navigation
Search
Home
Browse by Speaker
Home
Browse by Speaker
Browse by Speaker
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
O
Ocio, Enrique
Hospital Universitario Marqués de Valdecilla (IDIVAL), Santander, Spain
Abstract Session 10
Location: Room 718
Enrique Ocio
O'Donnell, Elizabeth
Dana-Farber Cancer Institute
Piecing together the evidence: Optimizing anti-CD38 quads in transplant-eligible NDMM
Location: Hall FG
Elizabeth O'Donnell
Ohlstrom, Denis
Georgia Institute of Technology
(OA-73) Longitudinal Multi-Omic Profiling Uncovers Immune Escape and Predictors of Response in Multiple Myeloma
Location: Room 718
Denis Ohlstrom
Oriol, Albert
Catalan Institute of Oncology and Josep Carreras Institute, Hospital Germans Trias i Pujol, Badalona, Spain
Clinical Considerations on Safety When Using BCMA BsAbs
Location: Hall FG
Albert Oriol
(OA-54) Efficacy of Mezigdomide Plus Dexamethasone and Bortezomib or Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma by Line of Therapy: Results from the Phase 1/2 CC-92480-MM-002 Trial
Location: Room 701
Albert Oriol
Orlowski, Robert
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center
Abstract Session 3
Location: Room 701
Robert Orlowski
(PA-379) Health-Related Quality of life (HRQoL) in Frail Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Isatuximab (Isa), Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) vs VRd Alone
Location: Room 714A
Robert Orlowski
